Novo Nordisk Faces a Two-Front Test: India's Oral Semaglutide Ambition and a Pivotal November 4 Report

Novo Nordisk is asking investors to weigh two very different timelines at once. One stretches to mid-2027, when oral semaglutide for obesity could reach the Indian market — if regulators allow it. The other lands on November 4, when the Danish drugmaker reports results for the first nine months of 2026 and the market finally gets hard numbers against which to test a growing pile of analyst skepticism.

Between those two dates sits a stock caught in a tug-of-war between valuation calls and operational doubts. Oddo BHF has raised its price target on the shares, according to media reports, while keeping its rating at "Neutral." That combination matters: a higher target reflects a revised valuation by the research house, not a buy signal, and it says nothing about how the business actually performed. Nor can the move be pinned down as the driver of any share-price action.

BMO Flags Ozempic Headwinds in the US

The more concrete caution comes from BMO Capital, which cut its price target and left its rating at "Market Perform." The broker pointed to demanding comparative figures and eroding US market share as risks to Ozempic sales — an assessment tied to the third quarter of 2026. That is an analyst expectation, not a reported result, and the distinction becomes decisive on November 4, when the company's own figures can be held up against those fears.

Meanwhile, Novo Nordisk keeps buying back its own stock, a capital measure running on a separate track from the debate over Ozempic. In a mandatory disclosure dated October 12, the company put spending under the program at DKK 10,558,876,422 through October 9. The buyback authorizes up to DKK 15 billion over twelve months starting February 4. Those purchases document how capital is being deployed; they do not answer BMO's questions about US Ozempic trends, and the two should not be conflated.

India Beckons, With a Regulatory Caveat

On the growth side, Novo Nordisk sees room to expand in India's GLP-1 market. Managing director Vikrant Shrotriya said on October 15 that a possible launch of oral semaglutide for obesity could come around mid-2027 — contingent on regulatory approval. Applications for a higher-dose semaglutide and for the oral obesity formulation were under review, according to media reports, which also cited Shrotriya's expectation of 15–20% annual growth for the Indian GLP-1 market.

Those are market expectations, not revenue forecasts for Novo Nordisk, and the mid-2027 timing is no confirmed sales start. A fast-growing overall market guarantees neither approval nor commercial success. The regulatory green light remains the gate through which any Indian launch must pass.

CagriSema Adds Clinical Depth — With Caveats

Development-stage data round out the picture. Novo Nordisk reported that post-hoc analyses of the Phase 3 REDEFINE 1 trial showed average weight loss of 25.0% in women after 68 weeks, versus 3.0% on placebo. The findings were presented at the annual meeting of the Menopause Society. CagriSema remains investigational, and these are retrospective analyses of an existing study rather than results from a new prospective trial — a distinction that matters when judging how much weight to give them.

A further analysis broke the data down by menopausal status: average weight loss came in at 26.7% for premenopausal women, 24.8% during the transition and 23.1% post-menopause. Because these cover different participant groups, they should not be read as a single uniform treatment outcome, and they say nothing about the regulatory review of oral semaglutide in India.

For investors, the takeaway is a company with two separate storylines: a possible broadening of its Indian offering and fresh evidence on an investigational drug. The clinical results strengthen the development case. The Indian launch, however, hinges on a regulatory decision that has yet to arrive — and the November 4 update will be the first real scorecard for everything else.